Among the patients, 115 samples corresponded to the TP53-mutant status, and 225 samples contained wild-type TP53. Importantly, patients with KRAS-mutated lung cancer with wild-type TP53 had a more optimized prognosis even after 120 months. This evidence concerns the gene KRAS and lung carcinoma.